Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals Plc director Ann Louise Merchant reported an initial holding of a stock option over 288 American Depositary Shares, with an exercise price of $475.00 per ADS and an expiration date of January 23, 2034. The option vests over four years, starting with 25% after one year and 6.25% every three months thereafter, so long as she continues in service.
Biodexa Pharmaceuticals Plc Chief Executive Officer Stephen Anthony Stamp filed an initial Form 3 reporting his beneficial ownership of stock options. He holds options to buy 859 American Depositary Shares at an exercise price of $327.5000 per ADS expiring in 2034, and options over 1,500, 25,000 and 15,000 Ordinary Shares at exercise prices of $28.0500, $7.4100 and $5.4000 per share, with expirations between 2029 and 2031. The filing lists existing option awards and does not show any new purchases or sales.
Biodexa Pharmaceuticals director Simon de Vries filed an initial ownership report showing a stock option holding. The option covers 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The underlying shares vest over four years, with 25% vesting after one year and the remainder vesting quarterly, subject to continued service.
Biodexa Pharmaceuticals Plc filed an initial insider report listing stock option holdings for Chief Financial Officer Fiona Mary Powell. The filing shows three option grants: one over 286 American Depositary Shares with a $327.5000 exercise price expiring on February 10, 2034, and two over ordinary shares covering 7,500 and 8,750 shares with exercise prices of $5.4000 and $7.4100, expiring on June 16, 2030 and July 14, 2031 respectively. Footnotes explain vesting schedules, note that some shares are already fully vested and exercisable, and clarify that each American Depositary Share represents 100,000 ordinary shares.
Biodexa Pharmaceuticals director Simon Turton has filed an initial ownership report for company securities. The filing shows a stock option over 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The option vests over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to continued service. Turton also reports direct ownership of 2,765 Ordinary Shares. Each American Depositary Share represents 100,000 Ordinary Shares of Biodexa Pharmaceuticals.
Biodexa Pharmaceuticals Plc reports a Schedule 13G showing Armistice Capital, LLC and Steven Boyd beneficially own 283,502 ADS, representing 9.99% of the class as of 12/31/2025. The filing states the shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager and Steven Boyd is managing member. The Reporting Persons report shared voting and dispositive power of 283,502 ADS and no sole voting or dispositive power. The Master Fund is identified as the direct holder and noted as having the right to receive dividends or sale proceeds.
Biodexa Pharmaceuticals PLC is registering for resale up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares held by selling shareholders, and is updating investors via a prospectus supplement and attached Form 6-K.
The company also reports an exclusive license and collaboration agreement with Otsuka Pharmaceutical, granting Biodexa rights outside Japan to develop, manufacture and commercialize MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors. Biodexa will handle development, manufacturing and commercialization in its licensed territory, with Otsuka eligible for an upfront payment, development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of certain sublicense income.
Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale by existing shareholders of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares. The supplement incorporates a new report describing a strategic licensing transaction.
The company entered an exclusive collaboration with Otsuka Pharmaceutical, obtaining worldwide rights outside Japan to develop, manufacture and commercialize MTX240 (OPB-171775), a Phase 1-ready molecular glue for gastrointestinal stromal tumors. Otsuka receives an upfront payment, potential development and regulatory milestones, and tiered mid-single-digit royalties on net sales, with MTX240 protected by composition of matter patents extending through 2037.
Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 4,349,000,000 ordinary shares represented by 43,490 American Depositary Shares by existing shareholders. The supplement also incorporates a Form 6-K describing a new license and collaboration agreement.
Biodexa obtained an exclusive license from Otsuka Pharmaceutical to develop, manufacture and commercialize MTX240 (OPB-171775) for all human therapeutic uses outside Japan. MTX240 is a Phase 1-ready molecular glue candidate initially aimed at gastrointestinal stromal tumors, with an upfront payment, development and regulatory milestones, and tiered mid-single digit royalties on net sales, supported by patents extending through 2037.
Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale of up to 2,846,100,000 ordinary shares represented by 24,861 American Depositary Shares. The supplement incorporates a Form 6-K describing an exclusive license and collaboration with Otsuka for MTX240, a Phase 1-ready molecular glue for gastrointestinal stromal tumours.
Biodexa receives exclusive rights to develop, manufacture and commercialize MTX240 outside Japan, while Otsuka retains Japanese rights. Otsuka receives an upfront payment, potential one-time development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of sublicense income. MTX240’s patents extend through 2037 and preclinical data suggest activity in tyrosine kinase inhibitor-resistant GIST models, aligning with Biodexa’s rare disease oncology strategy.